Since there is a lot of recent interest in Pluvicto, and RadioLigand therapy in general, in the community, I am surfacing some current content on this topic. This post is probably more of interest to members who are not following UroToday religiously.
1. From the Journal of Nuclear Medicine (Sept. 2023)
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
The consensus statement is the advice of a panel of experts to the MO and RO communities on how to think about integrating lutetium therapy into their practices on the basis of recently completed RCTs and FDA approvals.
jnm.snmjournals.org/content...
2. Two discussions from UroToday about the implications of this consensus statement in clinical practice
2.a Oliver Sartor, Heather Jacene and Alicia Morgan (Nov. 2023)
urotoday.com/video-lectures...
2.b Philip Koo and Thomas Hope (Sept. 2023)
VISION Trial Results Being Released
After Xtandi, 177Lu-PSMA-617 or BAT?
Treating the primary cancer in metastatic PCa. Etc.
Good video for those interested in Salvage Radiation
